“Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo”, J of Skin, vol. 3, p. S53, Nov. 2019, doi: 10.25251/skin.3.supp.53.